**PHASE I TRIAL ENROLLMENT**

**Eligibility Criteria**
- Patients with confirmed, metastatic, unresectable solid tumors which express HER2 after at least 2 lines of therapy, at least 1 measurable lesion per RECIST version 1.1, ECOG performance score 0-1, grade 2 or baseline for any prior treatment related toxicity.
- Without prior anti-cancer therapies.
- With a current or prior anti-cancer therapy.

**COHORTS**
- Cohort 1: Demographics & Tumor-Intrinsic Characteristics
  - **Tumor Type (%)**
    - Breast: 6 (25.0%)
    - Gastrointestinal: 22 (95.0%)
    - Other: 1 (4.0%)
  - **Sex:**
    - Male/Female: 10/0
  - **Median Age (Range):** 65.5 (40-70)
  - **IL-6 Decrease (%):** 4.5 (2.0-12)
  - **Expansion:** 4 (50.0%)
  - **N:** 8

**TAC01-HER2 SCIENCE**

**Key Features of TAC-HER2 Technology**
- TAC-HER2 Selectively targets HER2.
- TAC-HER2 is independent of MHC.
- TAC-HER2 requires endogenous TCR for T-cell activation.
- TAC-HER2 incorporates the co-receptors and recuits the TCR complex, mimicking natural TCR activation.

**BIOMARKER DATA: FIRST PATIENT RESPONSE**

**Blood Pharmacokinetics**
- **27P-gamma:** IL-12 (p70) IL-6

**TUMOR REGRESSION: FIRST PATIENT RESPONSE**

**Gastrointestinal lymph Node in Patient 0203-0021**

**Day 28**
- Baseline Day 0 (2.00 cm)
- Reduces to 0.87 cm

**REFERENCE**